EUNETWORKS
14.12.2021 12:28:07 CET | Business Wire | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has expanded its long haul network into Poland, delivering three new routes to Warsaw. These routes deliver around 2,977km of newly lit fibre connecting Warsaw directly with Berlin and Hamburg, with the third route via Brno, supporting traffic to Prague, Bratislava and Vienna. This expansion, which took 9 months to deliver, supports euNetworks’ customers’ demand for better diversity into the region. The system is in service, carrying multiple Terabits of customer traffic on each span that will rapidly grow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005710/en/
The new long haul routes were designed to deliver a unique triverse topology to market. Each route lands in a separate data centre in Warsaw, with scope to further expand as new data centres come into service in the region. The north route is 924km long, extends from Berlin and Hamburg and is unique in the market. Its route diversity also enables customers to bypass Berlin should they need to. The middle route is 845km long, running from euNetworks’ Berlin data centre facility into Warsaw. The south route, at 1,178km, delivers the shortest path to market between Vienna and Warsaw and enables Bratislava in Slovakia as a new point of presence for euNetworks along the way.
These routes connect into the key data centres and data centre hubs in Warsaw. This investment supports euNetworks’ customers’ bandwidth needs in this important market as well as onwards diversity and triversity to the rest of Europe. euNetworks’ long haul network now spans 17 countries, connecting 53 cities. Combined with euNetworks’ extensive metro networks in 17 cities, the long haul network enables any data centre to any data centre connectivity between all these metros on their owned and operated fibre, end-to-end.
The expansion East follows deployment of additional critical infrastructure linking the UK and the Netherlands, with euNetworks’ latest Super Highway along with subsea cable Scylla going live in September 2021.
“Warsaw is an exciting new region for data centre growth and is an important market experiencing strong bandwidth growth,” said Paula Cogan, President, euNetworks. “It’s a growing cloud region in Europe, with its geographic position making it a key connectivity hub for hyperscalers and cloud service providers. We continue to develop our network in support of our customers’ bandwidth requirements across Europe. Our expansion into Poland enables us to continue to offer a seamless and end to end data centre connectivity experience for our customers on our network with the same service delivery and support experience they have come to value.”
euNetworks’ 100g and 400G Wavelengths, 1G and 10G Ethernet, Cloud Connect and Multi Service Port products and solutions are now available in Warsaw, with plans for additional direct connection to further data centres in the region and in Warsaw to support customers’ needs in the future.
euNetworks builds and invests in its city and long haul fibre networks to connect the key data centres and data centre hubs across Europe. The company builds Super Highways on long haul routes that are critical to Europe’s future international bandwidth needs and uses low loss fibre on these routes to deliver a low cost per bit long haul solution for its customers.
About euNetworks
euNetworks is a bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 465 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005710/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom